- Home
- IMMX vs MRSN Comparison
IMMX vs MRSN Comparison
Compare IMMX & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- MRSN
- Stock Information
- Founded
- IMMX 2014
- MRSN 2001
- Country
- IMMX United States
- MRSN United States
- Employees
- IMMX 21
- MRSN N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- MRSN Health Care
- Exchange
- IMMX Nasdaq
- MRSN Nasdaq
- Market Cap
- IMMX 54.9M
- MRSN 40.7M
- IPO Year
- IMMX 2021
- MRSN 2017
- Fundamental
- Price
- IMMX $2.34
- MRSN $0.34
- Analyst Decision
- IMMX Strong Buy
- MRSN Strong Buy
- Analyst Count
- IMMX 1
- MRSN 5
- Target Price
- IMMX $7.00
- MRSN $5.75
- AVG Volume (30 Days)
- IMMX 360.1K
- MRSN 3.0M
- Earning Date
- IMMX 06-10-2025
- MRSN 05-15-2025
- Dividend Yield
- IMMX N/A
- MRSN N/A
- EPS Growth
- IMMX N/A
- MRSN N/A
- EPS
- IMMX N/A
- MRSN N/A
- Revenue
- IMMX N/A
- MRSN $34,006,000.00
- Revenue This Year
- IMMX N/A
- MRSN N/A
- Revenue Next Year
- IMMX N/A
- MRSN N/A
- P/E Ratio
- IMMX N/A
- MRSN N/A
- Revenue Growth
- IMMX N/A
- MRSN N/A
- 52 Week Low
- IMMX $1.26
- MRSN $0.26
- 52 Week High
- IMMX $2.71
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- IMMX 61.49
- MRSN 46.86
- Support Level
- IMMX $1.89
- MRSN $0.34
- Resistance Level
- IMMX $2.50
- MRSN $0.38
- Average True Range (ATR)
- IMMX 0.17
- MRSN 0.04
- MACD
- IMMX 0.00
- MRSN 0.00
- Stochastic Oscillator
- IMMX 73.77
- MRSN 33.64
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.